Sign up to save your podcasts
Or
Share DPYD Variant Dosing & ICIs In Pancreatic Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
DPYD Variant Dosing & ICIs In Pancreatic Cancer
Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651
Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
View all episodes
By John Bossaer
4.9
179179 ratings
Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651
Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
More shows like OncoPharm
View all
JAMA Editors' Summary
128 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
478 Listeners
The Curbsiders Internal Medicine Podcast
3,322 Listeners
Up First from NPR
56,141 Listeners
Core IM | Internal Medicine Podcast
1,089 Listeners
The ONS Podcast
197 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
695 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
320 Listeners
The Curious Clinicians
364 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
37 Listeners